Found: 47
Select item for more details and to access through your institution.
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
- Published in:
- Pharmacology Research & Perspectives, 2018, v. 6, n. 1, p. 1, doi. 10.1002/prp2.371
- By:
- Publication type:
- Article
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 6, p. 587, doi. 10.1002/cpdd.471
- By:
- Publication type:
- Article
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 639, doi. 10.1007/s40257-024-00869-w
- By:
- Publication type:
- Article
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 1, p. 127, doi. 10.1007/s40257-023-00810-7
- By:
- Publication type:
- Article
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 1, p. 97, doi. 10.1007/s40257-022-00738-4
- By:
- Publication type:
- Article
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
- Published in:
- American Journal of Clinical Dermatology, 2021, v. 22, n. 5, p. 693, doi. 10.1007/s40257-021-00618-3
- By:
- Publication type:
- Article
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
- Published in:
- American Journal of Clinical Dermatology, 2021, v. 22, n. 4, p. 541, doi. 10.1007/s40257-021-00604-9
- By:
- Publication type:
- Article
Immune Restoration With Antiretroviral Therapies.
- Published in:
- JAMA: Journal of the American Medical Association, 2000, v. 284, n. 2, p. 223, doi. 10.1001/jama.284.2.223
- By:
- Publication type:
- Article
Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 10, p. 1098, doi. 10.1002/cpdd.1465
- By:
- Publication type:
- Article
Granulocyte-Macrophage Colony-Stimulating Factor Induces Modest Increases in Plasma Human Immunodeficiency Virus (HIV) Type 1 RNA Levels and CD4[sup+] Lymphocyte Counts in Patients with Uncontrolled HIV Infection.
- Published in:
- Journal of Infectious Diseases, 2003, v. 188, n. 12, p. 1804
- By:
- Publication type:
- Article
Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients.
- Published in:
- Journal of Infectious Diseases, 2003, v. 187, n. 3, p. 504, doi. 10.1086/368206
- By:
- Publication type:
- Article
Interleukin-2 Increases CD4+ Lymphocyte Numbers but Does Not Enhance Responses to Immunization: Results of A5046s.
- Published in:
- Journal of Infectious Diseases, 2003, v. 187, n. 2, p. 320, doi. 10.1086/346056
- By:
- Publication type:
- Article
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
- Published in:
- BMC Dermatology, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12895-015-0025-y
- By:
- Publication type:
- Article
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
- Published in:
- BMC Dermatology, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12895-015-0025-y
- By:
- Publication type:
- Article
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2077, doi. 10.1007/s13555-022-00764-4
- By:
- Publication type:
- Article
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 771, doi. 10.1007/s13555-022-00694-1
- By:
- Publication type:
- Article
Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin.
- Published in:
- AAPS Journal, 2017, v. 19, n. 4, p. 1218, doi. 10.1208/s12248-017-0094-4
- By:
- Publication type:
- Article
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4<sup>+</sup> Cell Rises in HIV-Infected Patients.
- Published in:
- PLoS ONE, 2010, v. 5, n. 10, p. 1, doi. 10.1371/journal.pone.0013188
- By:
- Publication type:
- Article
Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk.
- Published in:
- PLoS ONE, 2008, v. 3, n. 4, p. 1, doi. 10.1371/journal.pone.0002021
- By:
- Publication type:
- Article
Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients.
- Published in:
- Journal of Infectious Diseases, 2011, v. 203, n. 2, p. 237, doi. 10.1093/infdis/jiq030
- By:
- Publication type:
- Article
Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138.
- Published in:
- Journal of Infectious Diseases, 2006, v. 194, n. 12, p. 1677, doi. 10.1086/509261
- By:
- Publication type:
- Article
330 Safety of abrocitinib in 3582 patients with moderate-to-severe atopic dermatitis with over 900 patients exposed for almost 2 years.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii20, doi. 10.1093/bjd/ljac140.025
- By:
- Publication type:
- Article
Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 8, p. 3856, doi. 10.1111/bcp.15334
- By:
- Publication type:
- Article
Proteína C-reactiva ultrasensible, estado nutricional y perfil bioquímico en escolares mexicanos.
- Published in:
- Revista Medica del IMSS, 2014, v. 52, n. 4, p. 398
- By:
- Publication type:
- Article
Discontinuation of Mycobacterium aviumComplex Prophylaxis in Patients with Antiretroviral Therapy-Induced Increases in CD4 1 Cell Count.
- Published in:
- Annals of Internal Medicine, 2000, v. 133, n. 7, p. 493, doi. 10.7326/0003-4819-133-7-200010030-00008
- By:
- Publication type:
- Article
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
- Published in:
- Rheumatology, 2019, v. 58, n. 1, p. 70, doi. 10.1093/rheumatology/key250
- By:
- Publication type:
- Article
Cytotoxic T-Cell Activity and Progression of HIV Disease: Abstract and Commentary.
- Published in:
- JAMA: Journal of the American Medical Association, 1998, v. 279, n. 3, p. 242, doi. 10.1001/jama.279.3.242
- By:
- Publication type:
- Article
Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.
- Published in:
- European Journal of Clinical Pharmacology, 2009, v. 65, n. 11, p. 1081, doi. 10.1007/s00228-009-0725-5
- By:
- Publication type:
- Article
Asociación de la proteína C-reactiva ultrasensible con la composición de la dieta en niños escolares mexicanos.
- Published in:
- Investigación Clínica, 2017, v. 58, n. 1, p. 44
- By:
- Publication type:
- Article
Contribution of a European‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 7, p. 1155, doi. 10.1002/art.41655
- By:
- Publication type:
- Article
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 9, p. 1450, doi. 10.1002/art.40911
- By:
- Publication type:
- Article
Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 5, p. 685, doi. 10.1002/art.40780
- By:
- Publication type:
- Article
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 10, p. 1960, doi. 10.1002/art.40189
- By:
- Publication type:
- Article
Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 11, p. 2924, doi. 10.1002/art.38779
- By:
- Publication type:
- Article
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 10, p. 2675, doi. 10.1002/art.38745
- By:
- Publication type:
- Article
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 5, p. 709, doi. 10.1007/s40262-021-01104-z
- By:
- Publication type:
- Article
Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Relationship between lymphocyte count and risk of infection in Japanese rheumatoid arthritis patients treated with tofacitinib.
- Published in:
- Modern Rheumatology, 2024, v. 34, n. 6, p. 1115, doi. 10.1093/mr/roae030
- By:
- Publication type:
- Article
Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths during 1995-1999.
- Published in:
- Clinical Infectious Diseases, 2001, v. 32, n. 10, p. 1487, doi. 10.1086/320164
- By:
- Publication type:
- Article
Use of Cellular HIV DNA to Predict Virologic Response to Maraviroc: Performance of Population-Based and Deep Sequencing.
- Published in:
- Clinical Infectious Diseases, 2013, v. 56, n. 11, p. 1659, doi. 10.1093/cid/cit105
- By:
- Publication type:
- Article
Deep V3 Sequencing for HIV Type 1 Tropism in Treatment-Naive Patients: A Reanalysis of the MERIT Trial of Maraviroc.
- Published in:
- Clinical Infectious Diseases, 2011, v. 53, n. 7, p. 732, doi. 10.1093/cid/cir493
- By:
- Publication type:
- Article
Drug Toxicity, HIV Progression, or Comorbidity of Aging: Does Tipranavir Use Increase the Risk of Intracranial Hemorrhage?
- Published in:
- Clinical Infectious Diseases, 2008, v. 47, n. 9, p. 1226, doi. 10.1086/592302
- By:
- Publication type:
- Article